FATE Filings — Fate Therapeutics, Inc. - FilingSpy
FATE
Fate Therapeutics, Inc.
A San Diego biotech that grows "off-the-shelf" cell therapies for cancer and autoimmune disease. Using induced pluripotent stem cells — adult cells rewound to an early, flexible state — it programs batches of immune cells (natural killer and T cells) that can be stored and given to many patients, unlike therapies made from each person's own cells. Founded in 2007 by stem-cell scientists, the name comes from its mission to "direct the fate" of cells into specific immune fighters. Its ticker symbol on the stock market is fittingly FATE.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -92.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.